Shares of Hoth Therapeutics Inc (NASDAQ:HOTH) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Zacks has also given Hoth Therapeutics an industry rank of 77 out of 256 based on the ratings given to its competitors.
Separately, Laidlaw started coverage on Hoth Therapeutics in a research report on Monday, May 20th. They issued a “buy” rating and a $10.00 target price for the company.
About Hoth Therapeutics
Hoth Therapeutics, Inc, a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures.
Further Reading: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.